9 Meters Biopharma Inc.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is de… Read more
9 Meters Biopharma Inc. (NMTRQ) - Total Liabilities
Latest total liabilities as of March 2023: $15.61 Million USD
Based on the latest financial reports, 9 Meters Biopharma Inc. (NMTRQ) has total liabilities worth $15.61 Million USD as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
9 Meters Biopharma Inc. - Total Liabilities Trend (2019–2022)
This chart illustrates how 9 Meters Biopharma Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
9 Meters Biopharma Inc. Competitors by Total Liabilities
The table below lists competitors of 9 Meters Biopharma Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ESPRIT HLDGS - Dusseldorf Stock Exchang
DU:ESHB
|
Germany | €3.80 Billion |
|
Videndum Plc
LSE:VID
|
UK | GBX253.00 Million |
|
Critical Metals Plc
LSE:CRTM
|
UK | GBX1.15 Million |
|
Alliance Witan Ord
LSE:ALW
|
UK | GBX402.29 Million |
|
IMC Exploration Group Public Limited Company
LSE:IMC
|
UK | GBX4.93 Million |
|
Unity Metals Limited
AU:UM1
|
Australia | AU$-21.67K |
Liability Composition Analysis (2019–2022)
This chart breaks down 9 Meters Biopharma Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 9 Meters Biopharma Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 9 Meters Biopharma Inc. (2019–2022)
The table below shows the annual total liabilities of 9 Meters Biopharma Inc. from 2019 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $30.75 Million | +258.77% |
| 2021-12-31 | $8.57 Million | +22.15% |
| 2020-12-31 | $7.02 Million | -52.94% |
| 2019-12-31 | $14.91 Million | -- |